Nrx pharmaceuticals (nasdaq:nrxp) announces final clinical trial results: superior safety combined with similar efficacy in the trial of nrx-101 compared to lurasidone in suicidal bipolar depression

Both drugs demonstrated > 50% response for treating depression. nrx-101 demonstrated a mean 76% reduction in symptoms of akathisia compared to lurasidone that was sustained over 42 days (effect size .37; p=0.025), using prespecified analytic methodology memorialized in fda special protocol agreement.
NRXP Ratings Summary
NRXP Quant Ranking